A Phase 1 Comparative Pharmacokinetic and Cardiac Safety Study of Two Intravenous Formulations of CO-101 in Patients With Advanced Solid Tumors.

Authors :: Stuurman, F.E.
Lolkema, M.P.
Huitema, A.D.R.
Soetekouw, P.M.M.B.
Rosing, H.
Rolfe, L.
Kaur, P.
Beijnen, J.H.
van Tinteren, H.
Voest, E.E.
Schellens, J.H.M.
Source :: Journal of Clinical Pharmacology. Aug2013, Vol. 53 Issue 8, p878-883. 6p.
Publication Year :: 2013
Abstract: The article discusses research on the first phase of a study on pharmacokinetics and cardiac safety, with a focus on intravenous formulations of the gemcitabine elaidic acid ester CO‐101 in patients with advanced tumors. Topics include bioequivalence tests, lipids, and phospholipids.

Subjects :: *CLINICAL trials
*CONFIDENCE intervals
*CROSSOVER trials
*MATHEMATICAL statistics
*MEDICAL cooperation
*HEALTH outcome assessment
*RESEARCH
*STATISTICAL sampling
*TUMORS
*PARAMETERS (Statistics)
*TREATMENT effectiveness
*DESCRIPTIVE statistics
*DEOXYCYTIDINE

Full Text Access

Tools